Self-assembled nanoformulations of paclitaxel for enhanced cancer theranostics

Pei, Qing; Jiang, Bowen; Hao, Dengyuan; Xie, Zhigang

doi:10.1016/j.apsb.2023.02.021

Cited by 13 publications

(3 citation statements)

References 237 publications

(369 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Self-assembly of small molecules is a relatively new strategy and claims to drastically improve cargo loading up to a hundred percent. , However, due to their high drug loading, even marginal off-target accumulation may have pronounced toxic effects and thus warrants advanced studies on their size/shape and surface functionalization to precisely target the tumor.…”

Section: Self-assembled Small Molecule Therapeuticsmentioning

confidence: 99%

Self-Assembled Nanobiomaterials for Combination Immunotherapy

Paul V,

Sharma,

Shanavas

2023

ACS Appl. Bio Mater.

View full text Add to dashboard Cite

Nanotechnological interventions for cancer immunotherapy are a rapidly evolving paradigm with immense potential. Self-assembled nanobiomaterials present safer alternatives to their nondegradable counterparts and pose better functionalities in terms of controlled drug delivery and phototherapy to activate immunogenic cell death. In this Review, we discuss several classes of self-assembled nanobiomaterials based on polymers, lipids, peptides, hydrogel, metal organic frameworks, and covalent−organic frameworks with the ability to activate systemic immune response and convert a "cold" immunosuppressive tumor mass to a "hot" antitumor immune cell rich microenvironment. The unique aspects of these materials are underpinned, and their mechanisms of combinatorial immunotherapeutic action are discussed. Future challenges associated with their clinical translation are also highlighted.

show abstract

Section: Self-assembled Small Molecule Therapeuticsmentioning

confidence: 99%

Self-Assembled Nanobiomaterials for Combination Immunotherapy

Paul V,

Sharma,

Shanavas

2023

ACS Appl. Bio Mater.

View full text Add to dashboard Cite

show abstract

“…Despite their promise, liposomal-targeted therapies face limitations due to the intricate tumor microenvironment, insufficient tumor site accumulation, and non-specific harm to healthy cells/tissues, all of which detrimentally impact the therapeutic efficacy of liposomes in cancer treatment [5,8,9]. Concerns also persist regarding cholesterol (Ch), a fundamental component in lipid system formulations, due to its potential to elicit allergic reactions, activate the complement system, and induce cardiovascular side effects, including pulmonary hypertension [10,11].…”

Section: Introductionmentioning

confidence: 99%

“…PTX elicits cytotoxicity in a concentration-and time-dependent manner [15]. Although PTX liposomal formulations are commercially available, suboptimal therapeutic efficacy necessitates improvements in carrier toxicity and stability [9,16]. Developing delivery systems that enhance liposomal stability and anti-proliferative activity could thus significantly improve their therapeutic impact.…”

Section: Introductionmentioning

confidence: 99%

Multifunctional Liposomes Co-Modified with Ginsenoside Compound K and Hyaluronic Acid for Tumor-Targeted Therapy

You,

Liu,

Chen

et al. 2024

Polymers

View full text Add to dashboard Cite

Liposomes show promise for anti-cancer drug delivery and tumor-targeted therapy. However, complex tumor microenvironments and the performance limitations of traditional liposomes restrict clinical translation. Hyaluronic acid (HA)-modified nanoliposomes effectively target CD44-overexpressing tumor cells. Combination therapy enhances treatment efficacy and delays drug resistance. Here, we developed paclitaxel (PTX) liposomes co-modified with ginsenoside compound K (CK) and HA using film dispersion. Compared to cholesterol (Ch), CK substantially improved encapsulation efficiency and stability. In vitro release studies revealed pH-responsive behavior, with slower release at pH 7.4 versus faster release at pH 5. In vitro cytotoxicity assays demonstrated that replacing Ch with CK in modified liposomes considerably decreased HCT-116 cell viability. Furthermore, flow cytometry and fluorescence microscopy showed a higher cellular uptake of PTX-CK-Lip-HA in CD44-high cells, reflected in the lower half maximal inhibitory concentrations. Overall, CK/HA-modified liposomes represent an innovative, targeted delivery system for enhanced tumor therapy via pH-triggered drug release and CD44 binding.

show abstract

Self‐Carrier Nanoparticles for Delivery of Paclitaxel and IDO Inhibitor to Boost Antitumor Chemo‐Immunotherapy

Li,

Pei,

Zhao

et al. 2024

Adv Funct Materials

Self Cite

View full text Add to dashboard Cite

The combination of chemotherapy and immunotherapy holds great potential in clinical treatment of advanced cancers. Whereas, the therapeutic outcome of chemotherapeutic and immune regulator is suboptimal due to their poor tumor availability and severe off‐target toxicity. Herein, self‐carrier nanoparticles (PSMT NPs) integrating a paclitaxel (PTX) prodrug and indoleamine 2,3‐dioxygenase 1 (IDO) inhibitor (1‐methyl‐tryptophan, 1MT) for tumor‐specific chemo‐immunotherapy is constructed. After internalization by cancer cells, PSMT NPs can respond to endogenous redox stimulus, and release PTX and 1MT. The released PTX can not only promote cell apoptosis via the intervention of cell mitosis but also initiate immunogenic cell death to facilitate the recruitment and activation of tumor‐infiltrating cytotoxic T lymphocytes. The concomitant 1MT can inhibit the IDO activity to exhaust regulatory T cells, thereby synergistically activating cytotoxic T lymphocytes. PSMT NPs exhibit potentiated antitumor output toward triple‐negative breast cancer and negligible systemic toxicity. This facile and versatile nanoplatform provides a promising strategy to cooperatively activate antitumor immunity for potentiated chemo‐immunotherapy.

show abstract

Self-assembled nanoformulations of paclitaxel for enhanced cancer theranostics

Cited by 13 publications

References 237 publications

Self-Assembled Nanobiomaterials for Combination Immunotherapy

Self-Assembled Nanobiomaterials for Combination Immunotherapy

Multifunctional Liposomes Co-Modified with Ginsenoside Compound K and Hyaluronic Acid for Tumor-Targeted Therapy

Self‐Carrier Nanoparticles for Delivery of Paclitaxel and IDO Inhibitor to Boost Antitumor Chemo‐Immunotherapy

Contact Info

Product

Resources

About